Abstract 178P
Background
Although splenic hilar lymph node (no.10 LN) dissection did not prolong survival in proximal gastric cancer, B4-type gastric cancer remains uninvestigated for the necessity of no.10 LN dissection. This is the first study investigating the treatment effect of no.10 LN dissection in B4-type gastric cancer.
Methods
We retrospectively reviewed patients who underwent total gastrectomy for B4-type gastric cancer between 2006 and 2016 in four major institutions in Korea. Using the inverse probability of treatment weighting (IPTW) using the propensity score, the long-term survival was compared between patients with and without no.10 LN dissection.
Results
There were 540.4 patients in the no.10-dissection group and 532.69 patients in the no-dissection group in the IPTW sample. The IPTW sample showed well-balanced clinicopathological characteristics between the two groups. The no.10-dissection group showed significantly better survival than the no-dissection group (5-ysr 45.7% vs. 38.6%, p=0.036). Multivariate analysis revealed that no.10 LN dissection was an independent prognostic factor (adjusted hazard ratio [HR] = 0.747, 95% CI = 0.593 – 0.940) after adjusting for other prognostic factors.
Conclusions
No.10 LN dissection during total gastrectomy may prolong survival in B4-type gastric cancer. A large randomized controlled trial may be warranted to validate these results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract